Back to all webinars
ASCO and EHA 2022: Practice-changing developments in lymphoma management
Christian Buske, Véronique Leblond, Wojciech Jurczak and Pier Luigi Zinzani cover the highlights in lymphoma management that were announced during ASCO and EHA 2022.
Speakers
Highlights in indolent lymphomas
Fast-forward to:
Obinutuzumab plus chemotherapy vs. rituximab plus chemotherapy in TN follicular lymphoma: The GALLIUM study
633bf67c6c032b10dca5a649
Zanubrutinib plus obinutuzumab vs. obinutuzumab in R/R follicular lymphoma: The ROSEWOOD study
633c17846c032b10dca5a779
BCL2 inhibitor BGB-11417 vs. BGB-11417 plus zanubrutinib in B-cell malignancies
633c1a696c032b10dca5a7eb
Zanubrutinib vs. ibrutinib in patients with WM: The ASPEN study
633c1b266c032b10dca5a810
Acalabrutinib in WM: 5-year follow-up
633c1d1a6c032b10dca5a85c
Bispecific CD20×CD3 antibodies in indolent lymphomas
633c1e5e6c032b10dca5a882
Highlights in CLL
Fast-forward to:
Is there still a role for chemotherapy in CLL?
633c26516c032b10dca5a8e2
Venetoclax plus obinutuzumab in untreated CLL: CLL14 study
633d268a6c032b10dca5a954
Zanubrutinib versus BR in untreated CLL: The SEQUOIA study
633d2b916c032b10dca5a9aa
Elevate-TN Phase 3 study in untreated CLL
633d2ea56c032b10dca5a9f1
MRD cohort in the CAPTIVATE study
633d321a6c032b10dca5aa30
Venetoclax monotherapy in del(17p) CLL
633d33896c032b10dca5aa65
Pirtobrutinib in CLL: The BRUIN study
633d344f6c032b10dca5aa7f
Highlights in aggressive lymphomas
Fast-forward to:
Glofitamab in R/R diffuse LBCL
633d3a006c032b10dca5aae0
Subcutaneous epcoritamab in R/R LBCL: EPCORE NHL-1
633d3d0c6c032b10dca5abaf
Axicabtagene ciloleucel (axi-cel) versus SoC in elderly patients with R/R LBCL: ZUMA 7
633d428d6c032b10dca5ac45
First-line ibrutinib in combination with BR and rituximab maintenance in MCL: The SHINE study
633d44ca6c032b10dca5ac5b
KTE-X19 in patients with R/R MCL: ZUMA-2
633d45c06c032b10dca5acc9
Panel discussion & Audience Q&A
Fast-forward to:
What was truly practice-changing in aggressive lymphomas?
633d48ab6c032b10dca5ad0e
What was truly practice-changing in indolent lymphomas?
633d49216c032b10dca5ad28
What was truly practice-changing in CLL?
633d4a046c032b10dca5ad42
Summary
No entries